Evidence map›Paper›PMID 40255421›Full record

ArticleFrontiers in oncology2025

Liver kinase B1 expression is associated with improved prognosis and tumor immune microenvironment features in small cell lung cancer.

Alessandro Dal Maso, Federica Ferrarini, Giovanni Esposito, Sonia Anna Minuzzo, Anna Maria Puggia, Federica Pezzuto, Elisabetta Zulato, Loc Carlo Bao, Mattia De Nuzzo, Alessandra Ferro and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Alessandro Dal MasoMedical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Federica FerrariniBasic and Translational Oncology, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Giovanni EspositoImmunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Sonia Anna MinuzzoDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Anna Maria PuggiaAnatomy and Pathological Histology, Veneto Institute of Oncology IOV - IRCCS, Castelfranco Veneto, Italy.
Federica PezzutoDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Elisabetta ZulatoBasic and Translational Oncology, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Loc Carlo BaoMedical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Mattia De NuzzoMedical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Alessandra FerroMedical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Stefano FregaMedical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Giulia PaselloMedical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Fiorella CalabreseDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Matteo FassanDepartment of Medicine, University of Padua, Padua, Italy.
Federico ReaDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Valentina GuarneriMedical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Stefano IndraccoloBasic and Translational Oncology, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Laura BonannoMedical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Small cell lung cancer (SCLC) is characterized by early metastatic potential and poor prognosis. Liver kinase B1 (LKB1) is a tumor suppressor and a cell metabolism regulator. LKB1 downregulation has been associated with a cold tumor immune microenvironment (TIME). We aimed to analyze the role of LKB1 in SCLC in relation to its association with overall survival (OS) and TIME components. Methods: We retrospectively evaluated SCLC patients consecutively treated at our institution from 1996 to 2020 with available tissue. LKB1, PD-L1 on tumor cells and on tumor immune-infiltrating cells, CD8, and FOXP3 were evaluated by immunohistochemistry (IHC), categorized according to predefined cutoffs. The primary endpoint was the description of LKB1 expression, and the secondary endpoints were the association with prognosis and TIME features. Results: Tissue samples of 138 out of 481 SCLCs were adequate for molecular analyses. Eighty patients had limited stage (LS) at diagnosis and 58 had extended stage (ES). The median LKB1 IHC score was 4. Patients with IHC score >4 ( Conclusion: LKB1 expression is a potential positive prognostic marker in SCLC. In this series, LKB1 expression was negatively associated with the presence of CD8

Indexed as

immunohistochemistryliver kinase B1overall survivalserine/threonine kinase 11small cell lung cancertumor immune microenvironment

Identifiers

PMID40255421
PMCPMC12006004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.